[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652415":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":55,"collaborators":58,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":26,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":87,"whyStopped":26,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Oman Ministry of Health","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Single-Fraction Radiotherapy (SFRT)","EXPERIMENTAL","Participants will receive VMAT-basd radiotherapy to painful none metastasis, a total dose of 8 Gy delivered in a single fraction using CBCT based imaging guidance.",[13],"Radiation: Single-Fraction Radiotherapy (8Gy x 1#)",{"label":15,"type":16,"description":17,"interventionNames":18},"Multifraction Radiotherapy (MFRT)","ACTIVE_COMPARATOR","Participants will receive VMAT-basd radiotherapy to painful none metastasis, a total dose of 20Gy delivered in Five fractions using daily CBCT based imaging guidance.",[19],"Radiation: Multifraction Radiotherapy (20 Gy in 5 #)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Single-Fraction Radiotherapy (8Gy x 1#)","VMAT-based external beam radiotherapy planned to deliver 8 Gy in a single fraction with CBCT-based image guidance for the palliation of painful bone metastasis",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Multifraction Radiotherapy (20 Gy in 5 #)","VMAT-based external beam radiotherapy planned to deliver 20 Gy in Five fractions of 4 Gy each with daily CBCT-based image guidance for the palliation of painful bone metastasis",[15],[32],{"name":33,"affiliation":34,"role":35},"Balaji Subramanian Sitaraman, MBBS, DNB","Royal Hospital, Ministry of Health, Oman","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","+96871926769","balaji.radonc@gmail.com",[42],{"facility":43,"status":26,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":26},"Royal Hospital","Muscat","Muḩāfaz̧at Masqaţ","100","Oman","OM",{"type":50,"coordinates":51},"Point",[52,53],58.40778,23.58413,{"lat":53,"lon":52},{"type":35,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Balaji Subramanian Sitaraman","Principal Investigator \u002F Senior Specialist",[59],{"name":60,"class":6},"Royal Hospital, Oman","100652415","single-fraction-and-multifraction-arc-based-radiotherapy-for-painful-bone-metastases-100652415",false,"NCT07772206","Single Fraction and Multifraction Arc-Based Radiotherapy for Painful Bone Metastases","The SMART Trial: A Randomised Feasibility Study Comparing Single Fraction and Multifraction Arc-Based Radiotherapy for Painful Bone Metastases","SMART","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically proven malignancy\n* Radiological evidence of bone or spine metastases\n* Pain score ≥4 on Numeric Rating Scale (NRS-11)\n* ECOG Performance Status 0-3\n* Life expectancy ≥3 months.\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Spinal cord compression requiring emergency therapy\n* Previous radiotherapy to same site\n* Unstable pathological fracture requiring surgery\n* Pregnancy\n* Inability to provide consent\n* Oligometastatic bone metastases requiring Stereotactic Body Radiotherapy (SBRT)","ALL","18 Years",{"count":72,"type":73},70,"ESTIMATED","INTERVENTIONAL",[76],"NA","This prospective randomised pilot feasibility study will compare single-fraction radiotherapy (8 Gy × 1) with multifraction radiotherapy (20 Gy in 5 fractions) for the palliation of painful bone metastases. The study will evaluate pain response at 4 weeks following radiotherapy, together with feasibility, treatment compliance, toxicity, pain flare, retreatment, patient convenience and resource utilisation. The study will generate preliminary data to inform the design of a future definitive randomised trial.",[79,80],"Bone Metastases of a Malignant Tumor","Cancer Pain",[82,83,84,85,86],"Bone Metastases","Feasibility","Single fraction radiotherapy","Multifraction radiotherapy","Pain response,","NOT_YET_RECRUITING","2026-08-14",{"date":90,"type":91},"2026-08-19","ACTUAL",{"date":93,"type":73},"2026-09-01",{"date":95,"type":73},"2027-12-30",{"name":5,"class":6},1]